BRAF and melanoma: Our side-by-side comparison of efficacy and safety of dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib in patients with BRAF-mutant melanoma identified important differences in efficacy, safety, and tolerability.